75 results about "Latent Virus" patented technology

The invention discloses an application of a benzamide histone deacetylase inhibitor in preparation of virus reservoir reactivation drugs as well as a composition containing the benzamide histone deacetylase inhibitor. The composition has an obvious effect of activating a reservoir of multiple persistent infection viruses such as human immunodeficiency virus, hepatitis B virus and hepatitis C virus and can be combined with an antiviral agent to obtain a better treatment effect.

The invention discloses the application of RVX-208 as an HIV-1 latent infection reversing agent, belongs to the field of medicine, and relates to the application of RVX-208 (Apabetalone, RVX-000222) as an HIV-1 latent infection reversing agent. An important reason why HIV‑1 is difficult to be completely eliminated in the body is that HIV‑1 can lurk in the resting memory CD4 + in T cells. The RVX-208 of the present invention has good activity of activating HIV-1 latent cell pool in vitro, especially can efficiently activate the latent virus pool in HIV-infected patients, and can activate latent infection reversal agents such as protein kinase C with other mechanisms of action Drugs, histone deacetylase inhibitors and cytokines have a good synergistic effect. Compared with the known BET inhibitor JQ1, its in vitro cytotoxicity is greatly reduced, and the drug is safe and well tolerated. Therefore, RVX‑208 is expected to become a new and efficient HIV‑1 latent infection activator, so as to achieve the goal of completely eradicating the HIV‑1 latent infection pool and realizing the "functional" cure of HIV.

The invention belongs to the medicine field and relates to the application of a bromine structural protein BET inhibitor to anti-HIV-1 latency treatment. Experiments prove that the chemical has an HIV-1 latent cell activation induction effect without causing activation of T cells of the whole body, can achieve synergetic activation after being combined with a protein kinase c agonist or cytokines, and can kill activated latent infected cells after being combined with antiretroviral drugs, so as to accelerate the elimination of a latent virus storage. Furthermore, the bromine structural domain protein inhibitor can be used for preparing anti-HIV-1 latency drugs and can provide a new interventional way and strategy for complete cure of AIDS.

Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity. Based on the understanding that reactivation or latency are important to produce or sustain autoimmunity, then therapies directed against Epstein-Barr virus will also be effective therapies for the autoimmune manifestations of disease for which Epstein-Barr virus is responsible.

The invention relates to the field of medicine, in particular to a composition for activating an HIV latent virus and application thereof. The composition consists of a monoclonal antibody drug, a histone deacetylase inhibitor and a PKC activator, wherein the monoclonal antibody drug is selected from an anti-human CD3 monoclonal antibody and an anti-human CD28 monoclonal antibody, the histone deacetylase inhibitor is selected from at least one of vorinostat and valproic acid, and a PKC activator is 12-deoxyphorbol-13-acetic acid (Prostratin). The main obstacle to cure the HIV is that the HIV establishes a hidden 'reservoir' of viruses in the body at the very early stage of infection. The composition has the effect of significantly activating latent HIV-infected CD4+ T cells, can activate the HIV latent virus simultaneously at the cellular level, the chromatin level and the HIV-specific transcription factor level, can fully activate the HIV pre-virus in the resting CD4+ T cells withoutsignificant cytotoxic side effects and is a necessary way to HIV functional healing.

The invention provides a HIV latency-resistant effective part of euphorbia and a use thereof. Through an ingenious activity screening method, it is found that a traditional Chinese medicine euphorbia has effects of resisting AIDS. Through solvent extraction, extraction and column chromatography processes and the combination with activity screening, the HIV latency-resistant effective part of euphorbia is determined and is prepared; and the HIV latency-resistant effective part of euphorbia can be used as an active ingredient having effects of resisting AIDS. The HIV latency-resistant effective part of euphorbia has effects of HIV latency intervention, can be combined with antiretroviral drugs thereby promoting removal of latent virus reservoirs, and provides a novel approach for thorough curing of AIDS.

The invention relates to a drug for resisting HIV latency and applications thereof, and specifically relates to the HIV latency resisting effect of oxaliplatin and dilazep and the applications of oxaliplatin and dilazep in preparation of drugs for treating AIDS. Oxaliplatin and dilazep both has the HIV latency resisting effect, can be cooperatively used with antiretroviral drugs to eliminate activated cells that has been subjected to latent infection so as to accelerate the elimination of latent virus reservoir, and can be further used to prepared novel anti-AIDS drugs. The invention provides a novel way for radically curing AIDS.

The invention discloses a human source anti-tetanus exotoxin antibody (HTAT-Fab) and preparation method, comprising: constructing human immunity phage antibody bank, screening phage positive clone, further getting HTAT-Fab gene with a specific neutralization activity and high affinity. The gene can be expressed in the procaryotic cell such as E.coli, eukaryotic cell such as microzyme, or mammalian cell such as CHO, purifying to get highly purified HTAT-Fab with a strong tissue penetrability, a high affinity. The HTAT-Fab product can not only eliminate the allergic reaction generated by horse serum anti-tatanus antitoxin (TAT) (foreign protein), but also avoid the blood source for producing human tetanus immunoglobulin (HTIG) and the latent virus pollution.

The invention discloses a cultivation method of high dwarfing stock virus-free apple seedlings, and belongs to the technical field of apple cultivation. In order to solve the problems that the content of in-vivo viruses of the virus-free apple seedlings is increased constantly with extension of a cultivation process under the influence of external factors, the cultivation method of the high dwarfing stock virus-free apple seedlings is provided. For apple nursery stocks cultivated in the steps of nursery stock treatment, nutrient substrate cultivation, field planting, after-planting management and the like, the survival rate is improved after the apple nursery stocks are transplanted in a large field, and the antiviral ability of the virus-free apple seedlings is fundamentally improved. Compared with virus-free apple seedlings cultivated without using the cultivation method, with the extension of the cultivation process, the content of latent viruses of apples has no obvious rise, the virus-free cultivation of the apple seedlings is fully achieved, and the quality of apple trees is ensured.

A diagnostic panel includes a test for detecting at least one biomarker that indicates the presence of a virus. A kit includes the diagnostic panel, instructions for use, materials to take and apply samples to the panel, and descriptions of biomarker levels and their meaning. A method of detecting the presence of disease, by taking a sample of an individual, applies the sample to the diagnostic panel including at least one biomarker indicative of disease, detects the presence of at least one biomarker, compares levels of the biomarker to a baseline, and determines if the individual has a disease. Methods of determining the stage of a disease, monitoring the progress of disease treatments, determining viral suppression or rebound, and detecting latent virus are also provided.

A diagnostic panel including a test for detecting at least one biomarker that indicates the presence of a virus. A kit including the diagnostic panel, instructions for use, materials to take and apply samples to the panel, and descriptions of biomarker levels and their meaning. A method of detecting the presence of disease, by taking a sample of an individual, applying the sample to the diagnostic panel including at least one biomarker indicative of disease, detecting the presence of at least one biomarker, comparing levels of the biomarker to a baseline, and determining if the individual has a disease. Methods of determining the stage of a disease, monitoring the progress of disease treatments, determining viral suppression or rebound, and detecting latent virus.

The invention relates to a network cooperative defense system and method based on a community structure, wherein the system divides the whole network into a plurality of autonomous communities, and each autonomous community comprises a user host, a cooperative control center and a community internal security system; wherein the community internal security system comprises an intrusion detection module which is used for intrusion detection and notifying a cooperative control center if abnormal information exists; an information honeypot and honeynet module which is used for responding to a command sent by the cooperative control center and storing and continuously monitoring abnormal information so as to obtain virus characteristics; a firewall module which is used for access control and identity authentication in the user host and the router; an intrusion protection module which is used for assisting the intrusion detection module to clear data packets containing viruses; a collaborative defense strategy library module which is used for storing node defense strategies or security defense strategies; a cooperative control center which is used for generating an optimal defense strategy according to a detection analysis result. The systems and methods provided by the present disclosure inhibit latent virus propagation.

Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

The invention discloses a preparation method for a multiplex immunocolloidal gold test strip used for apple latent viruses. Compared with the prior art, the invention provides a novel means for rapid, specific and simple detection of main apple latent viruses. Research achievements in the invention allow the molecular variation, invasion prevalence and virulence status of latent viruses of apples produced in Shanxi Province to be determined; and the multiplex immunocolloidal gold test strip developed on the basis of the research achievements can accurately and rapidly diagnose whether a nursery stock or a rootstock carries a virus, so propagation and prevalence of a disease caused by the virus can be effectively controlled, and the output and quality of produced apples can be improved.

The present invention relates to, inter alia, an anti-microtubule agent for use in a method of treating a subject having a latent virus, the method comprising: administering the anti-microtubule agent and an anti-viral agent to the subject.

The invention discloses brefeldin A (BFA) and a derivative and application thereof. The brefeldin A has the extremely high anti-HIV latency activity, and the series compound is obtained through a static culture fermentation method and chemical modification. The brefeldin A and the derivative thereof are of a structure shown as a formula (I) (please see the formula in the description), wherein R1-R5 represent H, OH, CH3, OCH3 and (OCH3)2 or OCOCH3 respectively, and R6 represents CH3. The brefeldin A and the derivative thereof can serve as anti-HIV latency drugs and can be applied to preparation of a drug for treating an AIDS jointly with an antiretroviral drug, when the brefeldin A and the derivative thereof are jointly applied with the antiretroviral drug, the brefeldin A and the derivative thereof can enable latent HIVs in infected cells to be expressed, have the effect of intervening HIV latency and can clear the activated and infection-latent cells to accelerate clearance of a latent virus storage, and the wide application prospect is achieved.

The invention relates to a method for synchronously detecting four viruses of carnation, in particular to a method for synchronously detecting carnation mottle virus, latent virus, ringspot virus and necrotic spot virus. The invention discloses primers for synchronously detecting the four viruses, and the sequences of the primers are shown as SEQ ID No.1-8. The invention also discloses a method for synchronously detecting the four viruses, which comprises the following steps of: 1) extracting total RNA of the carnation; and 2) performing reverse transcription-multiplex polymerase chain reaction: performing reverse transcription of the RNA obtained in the step 1), performing synchronous amplification on a reverse transcription production by using four pairs of primers, and synchronously detecting the four viruses. The primers have good compatibility, and belts are clear and easy to identify; and by the method, the detection cost is reduced, the detection speed is improved, and the synchronization, high efficiency and sensitivity for detecting the viruses of the carnation are realized.

The invention provides isatin compounds as well as a preparation method and an application thereof. The compounds have the structure shown in a formula (I) and have good BRD4 protein inhibition activity, have huge application potential in the antitumor and anti-virus aspects and can be applied to preparation of BRD4 inhibitor drugs; meanwhile, the compounds have good HIV latent virus activation capability, have greatly reduced in-vitro cytotoxicity as compared with known HIV latent activators JQ1, are safer to use and have good tolerance.

The invention discloses a lotus latent virus double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit and preparation and detection methods. The kit comprises an ELISA micro-pore plate,an enzyme-labeled antibody, a buffer solution, a color-developing solution and a stop solution, the micro-pore plate is coated by an LLV specific polyclonal antibody, and the enzyme-labeled antibody is an LLV specific polyclonal antibody marked by horseradish peroxidase. According to the kit, the adopted immunogen is an LLV coat protein antigen expressed by genetic engineering. The invention alsodiscloses a detection method of a lotus latent virus. According to the kit and the methods, a rapid, sensitive and simple method is provided for detection of the lotus latent virus on the basis of serology, the methods can be economic and practical, and an effective detection method is provided for prevention and control of lotus latency in lotus production and preparation of virus-free seedlingsthereof.

The invention discloses application of resveratrol and analogs of resveratrol in serving as HIV latent virus reservoir activating agents.The inventor proves that resveratrol can effectively stimulate rising of expression of GFP protein and a P24 antigen in a cell model through the HIV latent cell model J-lat full length clone 10.6.Thus, resveratrol and derivatives thereof can be independently used or jointly used with other activating medicine for activating the HIV latent virus reservoir in the body of an HIV patient and can serve as an alternative medicine molecule for curing aids.

The invention provides isatin compounds as well as a preparation method and an application thereof. The compounds have the structure shown in a formula (I) and have good BRD4 protein inhibition activity, have huge application potential in the antitumor and anti-virus aspects and can be applied to preparation of BRD4 inhibitor drugs; meanwhile, the compounds have good HIV latent virus activation capability, have greatly reduced in-vitro cytotoxicity as compared with known HIV latent activators JQ1, are safer to use and have good tolerance.

The invention discloses a human source anti-tetanus exotoxin antibody (HTAT-Fab) and preparation method, comprising: constructing human immunity phage antibody bank, screening phage positive clone, further getting HTAT-Fab gene with a specific neutralization activity and high affinity. The gene can be expressed in the procaryotic cell such as E.coli, eukaryotic cell such as microzyme, or mammalian cell such as CHO, purifying to get highly purified HTAT-Fab with a strong tissue penetrability, a high affinity. The HTAT-Fab product can not only eliminate the allergic reaction generated by horse serum anti-tatanus antitoxin (TAT) (foreign protein), but also avoid the blood source for producing human tetanus immunoglobulin (HTIG) and the latent virus pollution.

The invention discloses application of Aspochalasin compounds to preparation of anti-HIV (human immunodeficiency virus)-latency drugs and acquired immune deficiency syndrome treating drugs. The Aspochalasin compounds are of the structure shown as formula I, wherein R1, R2, R3, R4 and R5 are one or more than two of hydrogen, hydroxyl, carbonyl, double bond, epoxy, methyl and alkane amide respectively and are the same or different from one another. The Aspochalasin compounds have HIV latency activating effect, can be used with antiretroviral drugs and are capable of removing activated latent infection cells to accelerate latent virus reservoir removal so as to be used for treating the acquired immune deficiency syndrome. Formula I.

Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Methods for treating HIV positive patients, and purging and eradicating latent HIV virus from a patient's system, are disclosed. The bulk of viral load is eradicated using conventional antiretroviral (ARV) therapy. Compounds that encourage viral production in the latent cells are then administered, preferably without activating those cells, while maintaining the ARV therapy. The administration of compounds that encourage viral production in latent cells is cycled, and after around 7-10 cycles, the methods can virtually eliminate latent HIV in the patient. Ideally, the ARV regimen includes at least one integrase inhibitor, at least one entry inhibitor, such as a CCR5 antagonist, and at least one, and preferably two, reverse transcriptase inhibitors. The compounds that encourage viral production in latent cells ideally include a combination of prostratin or a prostratin analog and an HDAC inhibitor, such as butyrate, valproate, or SAHA.

Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity. Based on the understanding that reactivation or latency are important to produce or sustain autoimmunity, then therapies directed against Epstein-Barr virus will also be effective therapies for the autoimmune manifestations of disease for which Epstein-Barr virus is responsible.

The invention discloses a broad bean latent virus M double-antibody sandwich enzyme-linked immunoassay kit as well as a preparation method and a detection method thereof. The test kit comprises a microwell plate for ELISA, an enzyme-labeled antibody, a buffer solution, a developing solution and a stop solution, the microwell plate is coated with a VCV-M specific polyclonal antibody with an amino acid sequence shown as SEQ ID No.3, and the enzyme-labeled antibody is an alkaline phosphatase labeled VCV-M specific polyclonal antibody. The immunogen adopted by the invention is a VCV-M coat proteinantigen expressed by genetic engineering, a rapid, sensitive, simple and convenient method is provided for VCV-M detection on the serological level, the method is economical and practical, and a certain effective method is provided for subsequent broad bean field planting and virus disease prevention and control.

The invention provides a multiple RT-PCR detection method, which can simultaneously detect whether leaves, twigs, flowers or fruits of an apple tree bring three latent viruses namely apple chlorotic leaf spot virus, apple stem grooving virus, and apple stem pitting virus, and three apple scar skin viroids namely apple scar skin viroid, apple dimple fruit viroid, and apple fruit crinkle viroid or not. The detection method has the advantages of clear detection result, convenient operation, rapid reaction, and high sensitivity, and overcomes the shortages of time consuming, tedious steps, difficulty in distinguishing the stripes, and low sensitivity in the prior art. The invention provides a rapid detection method, which is easy for promotion and application, for detecting apple viruses.

The invention belongs to the medical field and relates to an application of 4-dimethyl amino nitrogen-5-hydroxy-formyl-hexyl amine for preparing an anti-human immunodeficiency virus (HIV) latent medicine. The compound has the effect on inducing activation of HIV latent cells, and the compound can be added into a cell culture fluid to induce activation of the HIV latent cells. The compound can be combined with a methyltransferase inhibitor or cell factors or an NF-kB signal activator to form an anti-HIV medicine composition; and the compound can also be combined with the existing HIV medicines to better inhibit and eliminate HIV viruses. Compared with the similar compounds, the compound of the invention has better effect on inducing activation of the HIV latent cells and lower cell toxicity. Especially, the compound can be combined with antiretroviral agents to kill the activated cells of latent infection, thereby accelerating the elimination of a latent virus reservoir. The invention provides a new method and way for thoroughly curing the acquired immune deficiency syndrome (AIDS).